Foghorn Therapeutics (FHTX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

FHTX Foghorn Therapeutics

Watchlist

8.880
-0.390-4.21%

Close Sep 12 16:00 ET

491.32MMarket Cap-4601P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Press Release: Foghorn Therapeutics Strengthens Leadership Team With Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
Dow JonesSep 3 07:00 ET
Jefferies Initiates Foghorn Therapeutics(FHTX.US) With Buy Rating, Announces Target Price $18
Moomoo NewsSep 3 05:32 ET · Ratings
Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 81.16%: Read This Before Placing a Bet
Yahoo FinanceSep 2 09:55 ET
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September
newsfilter.ioAug 28 07:00 ET
Flagship Pioneering and Quotient Therapeutics Announce Agreement to Identify Potential Novel Targets for the Treatment of Cardiovascular and Renal Diseases Under Strategic Partnership With Pfizer
newsfilter.ioAug 28 06:30 ET
What Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) 28% Share Price Gain Is Not Telling You
Simply Wall StAug 24 08:38 ET

Comments

Jaguar8

May 20 08:54

$Foghorn Therapeutics (FHTX.US)$
NEWS
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants

Trytosaveabit

Apr 9 15:59

Update! Watching

$Foghorn Therapeutics (FHTX.US)$ Foghorn Therapeutics Inc. is set to share updates on its cancer research pipeline during a conference call and webcast on April 9, 2024, coinciding with the AACR Annual Meeting. The company will outline progress in its preclinical trials, including the development of promising new inhibitors and degraders, with the intention of engaging with investors about these advancements. These forward-looking statements, while offering insights into potential...

Jaguar8

Apr 9 15:32

$Foghorn Therapeutics (FHTX.US)$
NEWS
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced plans to host a conference call and webcast on April 9th to review key pipeline programs, including FHD-286 for AML and new preclinical data for FHD-909 and selective CBP and EP300 degrader programs.

Moomoo AI

Mar 10 08:40

Foghorn Therapeutics' revenue estimates downgraded by analysts, expected losses per share increased. The company's slower growth compared to industry peers could be a concern for shareholders.